CMD Bioscience LLC is a privately held company dedicated to the discovery and early-stage validation of lead peptides for use in the pharmaceutical, biotech, and diagnostic industries.

Scientific Advisory Board

David Beveridge, PhD

David Beveridge, Ph.D. is University Professor of the Natural Sciences and Mathematics, and Professor of Chemistry and Director NIGMS Molecular Biophysics Training Program at Wesleyan University. His current research involves theoretical studies and computational modeling studies on the structure, motions, solvation, and ligand binding properties of DNA, RNA and proteins using molecular dynamics simulation-based techniques.

Benjamin Wolozin, MD, PhD

Benjamin Wolozin, M.D., Ph.D. is a professor of Pharmacology and Neurology at the Boston University School of Medicine. Dr. Wolozin’s research investigates the pathophysiology of neurodegenerative diseases. His research on Parkinson’s Disease focuses on understanding the interaction between genetic factors implicated in the disease and environmental factors utilizing cell culture, mammalian brain slice culture and transgenic lines of C. elegans. Results are then investigated further in transgenic/knockout mice and in human brain samples or cell lines from patients. His projects also focus on identifying pharmacological strategies for Parkinson’s disease.  The research on Alzheimer’s disease focuses on the interaction between the proteins that produce beta-amyloid and the genes that regulate cholesterol metabolism. Finally, Dr. Wolozin has an active epidemiological research program that examines the effects of FDA-approved medications on the incidence and progression of both Alzheimer’s and Parkinson’s disease.

Erick Suchanek, PhD

Dr Suchanek received his PhD in biochemistry and biophysics from John's Hopkins Medical School in Baltimore, MD. Dr Suchanek worked for Proctor and Gamble for over 20 years beginning as a company scientist assuming increasing roles of responsibility. He retired in 2009 as Section Head for the Global Modeling Community. Dr Suchanek has extensive industrial expertise in small molecule drug design methods and QSAR and is experienced in methods for conformer analysis and optimization, de novo drug design, pharmacophore modeling, molecular mechanics, quantum mechanics, and virtual screening.

Victor J. Hruby, PhD

Dr Hruby received his PhD from Cornell University and is Regents Professor Emeritus of Chemistry, Professor Emeritus of Biochemistry and Molecular Biophysics, Professor Emeritus, Arizona Research Laboratories, Professor Emeritus of Neuroscience, Professor Emeritus of Medical Pharmacology at the University of Arizona. Dr Hruby's research focuses on the design, synthesis, and analysis of biologically active peptides and peptide mimetics, with a special emphasis on the hormones and neurotransmitters affecting human behavior. Dr. Hruby is a world-renowned expert in the fields of rational antihormone development, design and asymmetric synthesis of conformationally constrained amino acids, peptides and peptide mimetics, and in the use of NMR and other physical methods to examine peptide and peptidomimetic conformations.

Bernhardt L. Trout

Professor Trout received his SB and SM degrees from MIT and his PhD from the University of California at Berkeley. In addition, he performed postdoctoral research at the Max-Planck Institute. Prof. Trout’s research focuses on molecular engineering for the stabilization of biotherapeutics, crystallization, and the development of pharmaceutical separation processes. He is currently Director of the Novartis-MIT Center for Continuous Manufacturing and the Co-Chair of the Singapore-MIT Alliance Program on Chemical and Pharmaceutical Engineering. He has published over 80 papers and currently has 4 patent applications submitted.